Search

The article discusses the increasing knowledge about immunopathogenesis of HIV-1 infection that hit the U.S. It notes that a triple combination therapy including a protease inhibitor was introduced in 1996 and since then, several studies have given clear survival benefits to patients treated when they had CD4. However, some consequences limit the treatment. In response to the consequences, the hit hard and hit early approach was changed to a strategy best described as hit hard.